1. Introduction {#sec1-molecules-20-18597}
===============

Traditional Chinese Medicine (TCM) typically involves the prescription of natural products in a composite formula, and has been widely used due to its specificity, effectiveness and low toxicity. There are a growing number of people who are using TCMs to achieve optimal health and prevent diseases \[[@B1-molecules-20-18597],[@B2-molecules-20-18597],[@B3-molecules-20-18597],[@B4-molecules-20-18597],[@B5-molecules-20-18597]\]. Any prescribed formulas in TCM involve a complex system containing hundreds or even thousands of different chemical constituents. It is well accepted that the efficacy of TCM formulas is based on the synergistic effects of these components. Extensive efforts have been made to establish specific analytical methods in order to distinguish the chemical components in TCM prescriptions \[[@B6-molecules-20-18597],[@B7-molecules-20-18597],[@B8-molecules-20-18597],[@B9-molecules-20-18597],[@B10-molecules-20-18597],[@B11-molecules-20-18597],[@B12-molecules-20-18597]\]. Shexiang Tongxin dropping pill (STP) is a Chinese FDA-approved formula that includes a combination of seven medicinal ingredients, including *moschus*, *Radix rhizoma ginseng*, *Calculus bovis*, bear gall, *Venenum bufonis*, borneol and *Salvia miltiorrhiza*. STP has been widely used in China and Southeast Asia for the clinical treatment of cardiovascular diseases. Previous pharmacological studies have proposed that STP can protect endothelial cells from atherosclerotic lesions by decreasing levels of endothelin-1 (ET-1), C reactive protein (CRP), tumor necrosis factor-α (TNF-α) and increasing levels of nitrogen oxide in the blood \[[@B13-molecules-20-18597]\]. Moreover, STP can decrease levels of harmful lipids and improve abnormal hemorheology indices \[[@B14-molecules-20-18597]\]. These therapeutic properties have been attributed to the major components in the prescription formula of STP \[[@B15-molecules-20-18597],[@B16-molecules-20-18597],[@B17-molecules-20-18597],[@B18-molecules-20-18597],[@B19-molecules-20-18597],[@B20-molecules-20-18597],[@B21-molecules-20-18597]\].

Although the beneficial effects of STP have been well documented, the actual bioactive components of STP are still poorly understood. The constituents of each single herbal component in STP have been reported, however the chemical analysis of the final STP formula as a whole has not yet been elucidated \[[@B22-molecules-20-18597],[@B23-molecules-20-18597],[@B24-molecules-20-18597],[@B25-molecules-20-18597],[@B26-molecules-20-18597],[@B27-molecules-20-18597],[@B28-molecules-20-18597]\]. This is necessary because the effects of TCMs do not simply involve the accumulated effects of individual components, but rather encompass the interactions between various components as a whole. In addition, changes and losses of certain constituents often occur during the production process of STP extraction, concentration and infusion, hence the contents of each component may also be changed. Therefore, qualitative and quantitative analysis of the total constituents in STP as a whole provides a more meaningful and specific outcome compared to the individual analysis of each component. In order to provide valuable information for quality control, as well as screening of the critical bioactive components, it is necessary to develop a specific and sensitive analytical method to identify and characterize the compounds in STP.

High performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry (HPLC-Q-TOF-MS/MS) has become one of the most powerful analytical tools due to its high resolution and accurate mass measurements \[[@B29-molecules-20-18597],[@B30-molecules-20-18597],[@B31-molecules-20-18597],[@B32-molecules-20-18597],[@B33-molecules-20-18597],[@B34-molecules-20-18597],[@B35-molecules-20-18597],[@B36-molecules-20-18597],[@B37-molecules-20-18597],[@B38-molecules-20-18597],[@B39-molecules-20-18597]\]. By comparing multiple-stage mass spectra with those of reference compounds and literatures, the unknown constituents can be identified. In addition, simultaneous quantitation of multi-components by ultra-performance liquid chromatography coupled with triple-quadrupole tandem mass spectrometry (UPLC-QqQ-MS/MS) has also been widely used in the analysis of TCM \[[@B40-molecules-20-18597],[@B41-molecules-20-18597],[@B42-molecules-20-18597],[@B43-molecules-20-18597]\].

In this study, HPLC-ESI-Q-TOF method was established for separating and identifying the components in STP. All 41 components were identified based on their retention times and MS spectra data. Subsequently, UPLC-QqQ-MS/MS method was developed for the simultaneous quantitative analysis of 13 of the compounds in STP. This study represents the first detailed investigation into the components of STP and provides a valid method for its quality control and evaluation.

2. Results and Discussion {#sec2-molecules-20-18597}
=========================

2.1. Optimization of HPLC Conditions {#sec2dot1-molecules-20-18597}
------------------------------------

Chromatographic parameters were optimized to achieve a higher separation quality of the fingerprint chromatogram and a reduced analysis time. In order to obtain optimal chromatograms with good peaks and high sensitivity, different mobile phases including water/methanol and water/acetonitrile were examined. We determined that optimal separation of the analytes was achieved using water/acetonitrile as the mobile phase ([Figure S1](#app1-molecules-20-18597){ref-type="app"}). The retention behavior of the compounds on reversed-phase HPLC columns was significantly affected by the pH of the mobile phase. Therefore we compared the effect of different acids, including formic acid, trifluoroacetic acid and phosphoric acid, as well as the amount of acid added into the mobile phase. We determined that the use of formic acid provided the greatest improvement during chromatographic separation, and also enhanced the formation of ions ([Figure S2](#app1-molecules-20-18597){ref-type="app"}). The optimal conditions for a given factor was selected based on the observed peak capacity. The combination of the optimal factors and parameters, including chromatographic column, column temperature, mobile phase, flow rate and gradient elution program were analyzed in order to achieve the highest degree of separation for each peak ([Figure S3](#app1-molecules-20-18597){ref-type="app"} and [Figure S4](#app1-molecules-20-18597){ref-type="app"}).

2.2. HPLC-Q-TOF-MS/MS Qualitative Analysis of Chemical Constituents in STP {#sec2dot2-molecules-20-18597}
--------------------------------------------------------------------------

To characterize the chemical constituents in STP, HPLC-Q-TOF-MS/MS method was established. As shown in [Table 1](#molecules-20-18597-t001){ref-type="table"}, a total of 41 components were initially identified or characterized, and 15 of those were identified unambiguously by comparing their retention times, mass accuracy, and fragmentation behaviors with data from the corresponding reference standards \[[@B37-molecules-20-18597],[@B39-molecules-20-18597],[@B44-molecules-20-18597]\]. The remaining compounds were tentatively characterized based on MS data, and reference to available literature data. The mass error for molecular ions of all identified compounds was within ±9 ppm. The total ion chromatograms in positive and negative ion modes were displayed in [Figure 1](#molecules-20-18597-f001){ref-type="fig"}. All compounds were grouped into six types according to their structural characteristics, which included bufadienolides, triterpene saponins, tanshinones, salvianolic acids, bile acids and other types. The structures of all compounds are shown in [Figure 2](#molecules-20-18597-f002){ref-type="fig"}.

molecules-20-18597-t001_Table 1

###### 

Characterization of chemical constituents of STP by HPLC-Q-TOF-MS/MS.

  No.                Source                    Identification                       Rt (min)             Formula              Negative Ion (*m*/*z*)                       
  ------------------ ------------------------- ------------------------------------ -------------------- -------------------- ---------------------------- ----------- --- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1                  C & B                     Taurine                              3.7                  C~2~H~7~NO~3~S       124.0063                     124.0065    2   
  2                  R                         Salvianolic acid A                   23.8                 C~26~H~22~O~10~      493.1129                     493.1133    1   
  3                  C & B                     Bilirubin                            24.2                 C~33~H~35~N~4~O~6~   583.2551                     583.2518    6   583.2518, 469.3944,356.4968, 243.8168
  4                  G                         Ginsenoside Rk3                      NA                   C~36~H~60~O~8~       619.4204                     NA              
  5                  G                         Ginsenoside Rd                       24.9                 C~48~H~82~O~18~      945.5417                     945.5405    1   
  6                  R                         Tanshinaldehyde                      NA                   C~19~H~16~O~4~       307.0965                     NA              
  7                  G                         Ginsenoside Rg6                      NA                   C~42~H~70~O~12~      765.4784                     NA              
  8 ^a^              R                         Salvianolic acid B                   25.5                 C~36~H~30~O~16~      717.1450                     717.1454    0   717.1454, 537.0995, 527.9935, 493.1069, 339.0521, 321.0405, 295.0633
  9 ^a^              V                         Arenobufagin                         28.7                 C~24~H~32~O~6~       415.2115                     415.2115    0   415.2115, 397.2063, 371.2165, 353.2112, 277.1492, 196.5435, 151.0702
  10 ^a^             C & B                     TDCANa                               33.8                 C~26~H~44~NNaO~6~S   498.2884                     498.2885    0   498.2907, 475.3216, 458.8943, 391.5463
  11 ^a^             C & B                     TCA                                  33.8                 C~26~H~44~NO~7~S     514.2833                     514.2856    4   514.2856, 496.2486, 482.3441, 124.1263
  12                 G                         Ginsenoside Rf                       NA                   C~35~H~76~O~19~      799.4897                     NA              
  13                 V                         Gamabufotalin                        NA                   C~24~H~34~O~5~       401.2323                     NA              
  14                 G                         Notoginsenoside R2                   NA                   C~41~H~70~O~13~      769.4733                     NA              
  15                 G                         Ginsenoside Rb1                      40.5                 C~54~H~92~O~23~      1107.5946                    1107.5927   2   1107.5927, 945.5389, 783.4901, 765.4580, 621.4343, 553.2887, 472.2575, 459.3803, 323.0972, 263.0742, 221.0678, 179.0538, 179.0538, 161.0395, 143.0272, 131.0323, 125.0221, 119.0351, 113.0260, 101.0208
  16                 V                         Bufotalin                            41.1                 C~26~H~36~O~6~       443.2428                     443.2452    5   443.2452, 407.2732, 380.9754, 375.2916, 256.8133, 203.8251, 167.9242, 138.0325
  17 ^a^             G                         Ginsenoside Rh1                      41.8                 C~37~H~64~O~11~      683.4403                     683.4384    3   683.4384, 637.4330, 475.3704, 179.0470, 161.0398
  18                 C & B                     GCA                                  42.6                 C~26~H~43~NO~6~      464.3007                     464.3015    2   
  19 ^a^             C & B                     TDCA                                 42.8                 C~26~H~45~NO~6~S     498.2884                     498.2907    5   498.2907, 464.2945, 451.3111, 391.1261, 321.1686, 201.2573
  20                 V                         Resibufagin                          NA                   C~24~H~30~O~5~       397.2010                     NA              
  21                 G                         Ginsenoside Rb2                      43.7                 C~53~H~90~O~22~      1077.5840                    1077.5795   4   1077.5795, 945.5318, 915.1144, 783.0026, 765.1212, 621.3652, 311.9821, 293.6514, 191.8123, 149.1853
  22                 G                         Ginsenoside Re                       47.2                 C~48~H~82~O~18~      945.5417                     945.5433    2   945.5433, 880.9436, 799.2672, 765.1661, 637.2542, 475.2767, 218.9817
  23                 G                         Ginsenoside Rk1                      NA                   C~42~H~70~O~12~      765.4784                     NA              
  24 ^a^             V                         Bufalin                              NA                   C~24~H~34~O~4~       385.2373                     NA              
  25 ^a^             C & B                     CA                                   52.1                 C~24~H~40~O~5~       407.2792                     407.2811    5   407.2811, 389.2677, 363.2526, 325.6244, 289.2744, 233.8977, 215.3690, 205.9169
  26                 V                         Argentinogenin-3-lutarate-arginine   53.6                 C~38~H~58~N~4~0~8~   697.4171                     697.4121    7   697.4121, 651.4153, 535.5406, 489.3649, 179.0546
  27                 C & B                     TLCA                                 55.0                 C~22~H~44~NO~10~     482.2960                     482.2918    9   
  28                 G                         Ginsenoside Rg1                      55.3                 C~43~H~72~O~14~      811.4838                     811.4813    3   811.4813, 775.8988, 765.4577, 619.3911, 421.2024, 391.2774
  29                 C & B                     DCA                                  55.8                 C~24~H~40~O~4~       391.2843                     391.2854    3   
  30                 C & B                     GCDGA                                56.2                 C~26~H~43~NO~5~      448.3058                     448.3065    2   448.3065, 409.2741, 391.2853, 389.2658, 365.3004
  31 ^a^             C & B                     UDCA                                 56.8                 C~24~H~40~O~4~       391.2843                     391.2848    1   409.2741, 391.2739, 373.8139, 354.4757, 152.9965
  32 ^a^             C & B                     HDCA                                 57.4                 C~24~H~40~O~4~       391.2843                     391.2851    2   409.2741, 391.2853, 389.2658, 118.1248
  33 ^a^             V                         Resibufogenin                        NA                   C~24~H~32~O~4~       383.2217                     NA              
  34                 G                         Ginsenoside Rs3                      NA                   C~44~H~74~O~14~      825.4995                     NA              
  35 ^a^             V                         Cinobufagin                          NA                   C~26~H~34~O~6~       441.2272                     NA              
  36                 G                         Chikusetsusaponin Iva                61.6                 C~42~H~66~O~14~      793.4374                     793.4330    6   793.4330, 598.6542, 481.7612, 524.4589
  37                 G                         Ginsenoside 20S-Rg3                  NA                   C~42~H~72~O~13~      783.4889                     NA              
  38 ^a^             G                         ginsenoside Rg2                      68.9                 C~42~H~72~O~13~      783.4889                     783.4873    2   783.4873, 765.1686, 617.0004, 409.2952, 391.2852, 313.1097
  39 ^a^             C & B                     CDCA                                 68.9                 C~24~H~40~O~4~       391.2843                     391.2853    3   391.2739, 345.4757, 329.1213, 97.0589
  40                 C & B                     LCA                                  89.4                 C~24~H~40~O~3~       375.2894                     375.2888    2   
  41 ^a^             R                         Tanshinone IIA                       NA                   C~19~H~18~O~3~       293.1172                     NA              
  **No.**            **Source**                **Identification**                   **Rt (min)**         **Formula**          **Positive Ion (*m*/*z*)**                   
  **\[M + H\]^+^**   **Quasi-Molecular Ion**   **Error (ppm)**                      **MSMS (*m*/*z*)**                                                                     
  1                  C & B                     Taurine                              3.7                  C~2~H~7~NO~3~S       126.0219                     126.0222    2   126.0222, 115.3256, 108.8434, 97.2221, 91.7216
  2                  R                         Salvianolic acid A                   NA                   C~26~H~22~O~10~      495.1286                     NA              
  3                  C & B                     Bilirubin                            NA                   C~33~H~35~N~4~O~6~   584.2629                     NA              
  4                  G                         Ginsenoside Rk3                      24.5                 C~36~H~60~O~8~       621.4361                     621.4362    0   
  5                  G                         Ginsenoside Rd                       24.6                 C~48~H~82~O~18~      947.5574                     947.5501    8   
  6                  R                         Tanshinaldehyde                      24.6                 C~19~H~16~O~4~       309.1121                     309.1147    8   
  7                  G                         Ginsenoside Rg6                      24.6                 C~42~H~70~O~12~      767.4940                     767.4931    1   
  8 ^a^              R                         Salvianolic acid B                   25.8                 C~36~H~30~O~16~      719.1607                     719.1613    1   719.1613, 323.0496, 295.0572, 181.0460
  9 ^a^              V                         Arenobufagin                         28.4                 C~24~H~32~O~6~       417.2272                     417.2273    0   417.2273, 399.2188, 362.7495, 223.1056
  10 ^a^             C & B                     TDCANa                               33.2                 C~26~H~44~NNaO~6~S   500.4245                     NA              
  11 ^a^             C & B                     TCA                                  33.5                 C~26~H~44~NO~7~S     516.2990                     516.2984    1   
  12                 G                         Ginsenoside Rf                       34.0                 C~35~H~76~O~19~      801.5054                     801.5075    3   
  13                 V                         Gamabufotalin                        38.9                 C~24~H~34~O~5~       403.2251                     403.2267    4   403.2267, 385.9531, 367.1296, 349.4632, 331.8123
  14                 G                         Notoginsenoside R2                   39.0                 C~41~H~70~O~13~      771.4889                     771.4861    4   
  15                 G                         Ginsenoside Rb1                      39.9                 C~54~H~92~O~23~      1109.6102                    1109.6030   6   1109.6030, 935.5613, 878.7854, 646.6751, 443.3798, 407.3652, 325.1114, 217.1888, 163.0566, 145.0507, 127.0384, 85.0294
  16                 V                         Bufotalin                            41.1                 C~26~H~36~O~6~       445.2585                     445.2585    0   
  17 ^a^             G                         Ginsenoside Rh1                      NA                   C~37~H~64~O~11~      685.4521                     NA              
  18                 C & B                     GCA                                  42.3                 C~26~H~43~NO~6~      466.3163                     466.3132    7   466.3132, 337.2523, 319.2353, 295.2026, 288.1602, 213.1621, 209.1339, 201.1658
  19 ^a^             C & B                     TDCA                                 42.8                 C~26~H~45~NO~6~S     500.3040                     500.3042    0   
  20                 V                         Resibufagin                          42.8                 C~24~H~30~O~5~       399.2166                     399.2158    2   399.2158, 387.2519, 297.7655, 223.1439, 211.1011, 145.0999, 131.0982, 179.0841, 105.0709, 91.0525
  21                 G                         Ginsenoside Rb2                      43.1                 C~53~H~90~O~22~      1079.5997                    1079.5942   5   
  22                 G                         Ginsenoside Re                       46.5                 C~48~H~82~O~18~      947.5574                     947.5510    7   
  23                 G                         Ginsenoside Rk1                      46.6                 C~42~H~70~O~12~      767.4940                     767.4931    1   
  24 ^a^             V                         Bufalin                              49.1                 C~24~H~34~O~4~       387.253                      387.2527    1   387.2527, 370.9842, 352.9666, 340.2608, 255.2028
  25 ^a^             C & B                     CA                                   NA                   C~24~H~40~O~5~       409.2949                     NA              
  26                 V                         Argentinogenin-3-lutarate-arginine   53.2                 C~38~H~58~N~4~0~8~   699.4327                     699.4299    4   699.4299, 681.4053, 598.7017, 582.3791, 331.2027, 278.1446, 250.1590, 175.1200, 157.1072
  27                 C & B                     TLCA                                 NA                   C~22~H~44~NO~10~     483.3038                     NA              
  28                 G                         Ginsenoside Rg1                      NA                   C~43~H~72~O~14~      813.4995                     NA              
  29                 C & B                     DCA                                  NA                   C~24~H~40~O~4~       393.3000                     NA              
  30                 C & B                     GCDGA                                56.1                 C~26~H~43~NO~5~      450.3214                     450.3204    2   450.3204, 415.3174, 321.2607, 278.7283, 215.1679, 175.1452, 161.1349, 147.1140, 107.0885
  31 ^a^             C & B                     UDCA                                 NA                   C~24~H~40~O~4~       393.3000                     NA              
  32 ^a^             C & B                     HDCA                                 NA                   C~24~H~40~O~4~       393.3000                     NA              
  33 ^a^             V                         Resibufogenin                        57.7                 C~24~H~32~O~4~       385.2373                     385.2369    1   385.2369, 367.2214, 350.2243, 341.2244, 332.2025
  34                 G                         Ginsenoside Rs3                      57.8                 C~44~H~74~O~14~      827.5151                     827.5165    2   
  35 ^a^             V                         Cinobufagin                          57.9                 C~26~H~34~O~6~       443.2428                     443.2425    1   443.2425, 401.2288, 385.2322, 367.2210, 349.2129, 187.1473, 151.0382
  36                 G                         Chikusetsusaponin Iva                NA                   C~42~H~66~O~14~      795.4525                     NA              
  37                 G                         Ginsenoside 20S-Rg3                  68.6                 C~42~H~72~O~13~      785.5046                     785.5063    2   785.5063, 621.6871, 357.2785, 339.2647, 321.2458, 275.2027, 221.1526, 161.1345
  38 ^a^             G                         ginsenoside Rg2                      NA                   C~42~H~72~O~13~      785.5046                     NA              
  39 ^a^             C & B                     CDCA                                 NA                   C~24~H~40~O~4~       393.3000                     NA              
  40                 C & B                     LCA                                  NA                   C~24~H~40~O~3~       377.3050                     NA              
  41 ^a^             R                         Tanshinone IIA                       92.3                 C~19~H~18~O~3~       295.1269                     295.1266    0   295.1266, 280.4501, 277.1173, 266.0878, 262.0933, 249.1212, 235.0725, 225.1178, 221.1251, 207.0771

G: Ginsenoside; V: *Venenum bufonis*; R: Red-rooted salvia; C: *Calculus bovis*; B: Bear gall; ^a^ Compared with a reference standard.

![HPLC-Q-TOF-MS/MS total ion chromatogram (**A**) TIC of STP drug in positive mode (**B**) TIC of reference substances in positive mode (**C**) TIC of STP drug in negative mode (**D**) TIC of reference substances in negative mode. Standards are as follows: salvianolic acid B, arenobufagin, TDCA, TCA, Rg2, Rh1, bufalin, CA, UDCA, HDCA, resibufogenin, cinobufagin, CDCA, tanshinone IIA, and TDCANa.](molecules-20-18597-g001){#molecules-20-18597-f001}

![Chemical structures of the compounds identified in STP.](molecules-20-18597-g002){#molecules-20-18597-f002}

### 2.2.1. Compounds from Ginseng {#sec2dot2dot1-molecules-20-18597}

A total of 13 ginseng saponins were identified in this study, and these can be divided into those belonging to the protopanaxadiol (PPD) group, including ginsenoside Rd (Peak 5), ginsenoside Rf (Peak 12), ginsenoside Rg2 (Peak 38), ginsenoside Rk1 (Peak 23), ginsenoside Rs3 (Peak 34), and ginsenoside Rg3 (Peak 37); and the protopanaxatriol (PPT) group, including ginsenoside Rk3 (Peak 4), ginsenoside Re (Peak 22), ginsenoside Rb1 (Peak 15), ginsenoside Rb2 (Peak 21), ginsenoside Rh1 (Peak 17), ginsenoside Rg6 (Peak 7), and ginsenoside Rg1 (Peak 28). For saponin compounds, successive or simultaneous losses of sugar moieties are commonly produced in the negative MS/MS ion mode. In this study, ginsenoside Rb1 was used as an example to illustrate the fragmentation pathway of saponins as shown in [Figure 3](#molecules-20-18597-f003){ref-type="fig"}A. The precise molecular weight of ginsenoside Rb1 is 1107.5946 g/mol, and the main fragment ions including *m*/*z* 1107.5927 \[M − H\]^−^, 945.5389 \[M − H-Glc\]^−^, 783.4901 \[M − H-2Glc\]^−^, 765.4580 \[M − H-(Glc-H~2~O)\]^−^, and 459.3803 \[C~32~H~56~O~3~\]^−^ were observed via MS/MS screening. In addition, highly abundant ions at *m*/*z* 179.0538, 161.0395, 143.0272, 131.0323, 119.0351, 113.0260, and 101.0208 produced via cross fragmentation were also found.

### 2.2.2. Compounds from *Salvia miltiorrhiza* {#sec2dot2dot2-molecules-20-18597}

The main ingredients of *Salvia miltiorrhiza* were detected in this study, which included salvianolic acid A (Peak 2), salvianolic acid B (Peak 8), and tanshinone IIA (Peak 41). The main fragment ions of tanshinone IIA as analyzed by MS/MS screening were observed at *m*/*z* 295.1266 \[M + H\]^+^, 280.4501 \[M + H-CH~3~\]^+^, 225.1178 \[M + H-CHO\]^+^, 277.1173 \[M + H-H~2~O\]^+^, 262.0933\[M + H-H~2~O-CH~3~\]^+^, and 249.1212 \[M + H-H~2~O-CO\]^+^ in the positive ion spectrum ([Figure 3](#molecules-20-18597-f003){ref-type="fig"}B).

###### 

(**A**) The ESI-QTOF-MS spectra and the proposed fragmentation pathway of ginsenoside Rb1; (**B**) The ESI-QTOF-MS spectra and the proposed fragmentation pathway of tanshinone IIA; (**C**) The ESI-QTOF-MS spectra and the proposed fragmentation pathway of gamabufotalin; (**D**) The ESI-QTOF-MS spectra and the proposed fragmentation pathway of TDCA.

![](molecules-20-18597-g003a)

![](molecules-20-18597-g003b)

![](molecules-20-18597-g003c)

### 2.2.3. Compounds from Toad Skin Secretion *(Venenum bufonis)* {#sec2dot2dot3-molecules-20-18597}

Eight toad skin secretion compounds from *Venenum bufonis* were identified in this study. These compounds can be categorized into the *Venenum bufonis* I (VB I) group, which included arenobufagin (Peak 9), gamabufotalin (Peak 13), bufotalin (Peak 16), bufalin (Peak 24), and argentinogenin-3-adipate-arginine (Peak 26); and the *Venenum bufonis* II (VB II) group, including resibufagin (Peak 20), resibufogenin (Peak 33), and cinobufagin (Peak 35).

The mass fragmentation patterns were analyzed to verify the identification of these compounds. The results showed that the unconjugated bufosteroids can produce a series of neutral ions or positive ions containing rings A, B and C following the continuous loss of neutral H~2~O (18 Da) ion in the remaining steroidal rings. The main fragment ions of gamabufotalin include *m*/*z* 403.2267 as \[M + H\]^+^, 385.9531 \[M + H-H~2~O\]^+^, 367.1296 \[M − H~2~O-CO\]^+^, 349.4632 \[M + H-C~2~OH~3~\]^+^, and 265.1687 \[M + H-C~8~H~9~O~2~\]^+^ were observed in this study. The cleavage method of the bufosteroids without 16-hydroxyl substation showed obvious ion peaks of the lactonic ring E at *m*/*z* 121.7521 \[C~7~H~5~O~2~\]^+^ and *m*/*z* 137.9124 \[C~8~H~8~O~2~ + H\]^+^ in positive ion mode ([Figure 3](#molecules-20-18597-f003){ref-type="fig"}C).

### 2.2.4. Compounds from *Calculus bovis* and Bear Gall {#sec2dot2dot4-molecules-20-18597}

The major constituents of *Calculus bovis* and bear gall all have similar bile acid composition, and therefore we performed simultaneous analysis of these compounds. Eleven bile acids were identified, including taurine (Peak 1), bilirubin (Peak 3), TDCA (Peak 19), TCA (Peak 11), GCA (Peak 18), CA (Peak 25), UDCA (Peak 31), TLCA (Peak 27), GCDCA (Peak 30), HDCA (Peak 32), CDCA (Peak 39), DCA (Peak 29), and lithocholic acid (Peak 40).

In this study, four peaks (compounds 31, 32, 39, and 29) showed identical ions at *m*/*z* 391.2850 ± 4 ppm \[M**\*** − H\]^−^ and *m*/*z* 783.4830 ± 3ppm \[2M\* − H\]−. By comparison with reference standards, these four compounds were identified as UDCA (391.2848 \[M**\*** − H\]^−^), HDCA (391.2851\[M**\*** − H\]^−^), CDCA (391.2853 \[M**\*** − H\]^−^), and DCA (391.2854\[M**\*** − H\]^−^). The main fragment ions of compound 19 were observed at *m*/*z* 498.2907 \[M − H\]^−^, 475.3216 \[M − H-H~2~O\]^−^, 432.3157 \[M − H-HSO~3~\]^−^, and 391.2854 \[M + H-H~2~O-C~2~H~7~N\]^−^ in the negative ion spectrum. Furthermore, compound 19 showed the same fragmentation pathway to DCA at *m*/*z* 373.2737 \[M**\*** − H-H~2~O\]^−^, *m*/*z* 355.2632 \[M**\*** − H-2H~2~O\]^−^, *m/z* 347.2945 \[M**\*** − H-HCOO\]^−^ and *m*/*z* 329.2839 \[M**\*** − H-H~2~O-HCOO\]^−^ in the MS/MS spectrum, and therefore we deduced that compound 19 was TDCA ([Figure 3](#molecules-20-18597-f003){ref-type="fig"}D).

2.3. UPLC-QqQ-MS/MS Quantitative Analysis of Chemical Constituents from STP {#sec2dot3-molecules-20-18597}
---------------------------------------------------------------------------

The qualitative results indicated that ginsenoside Rg1, ginsenoside Rg3, cinobufagin, arenobufagin, bufalin, resibufogenin, tanshinone IIA, taurine, astragaloside, tauroursodeoxycholic acid, taurocholic acid, cholic acid, deoxycholic acid, and chenodeoxycholic acid were the major constituents in STP ([Figure 4](#molecules-20-18597-f004){ref-type="fig"}).

![The MRM chromatograms of 13 markers and internal standard: (1) taurine, (2) ginsenoside Rg1, (3) arenobufagin, (4) TDCA, (5) TCA, (6) bufalin, (7) CA, (8) cinobufagin, (9) resibufogenin, (10) ginsenoside Rg3, (11) CDCA, (12) DCA, (13) tanshinone IIA, (IS) astragaloside*.*](molecules-20-18597-g004){#molecules-20-18597-f004}

Furthermore, because of the similarity between their structures, retention time and ionization response in ESI-MS, astragaloside was chosen as the internal standard for the saponins, bile acids and tanshinones. In order to develop a sensitive and accurate quantitative method, the MS/MS fragmentation for each compound was investigated by direct infusion of the single standard solution into the mass spectrometer, and the resulting mass spectra of product ions were recorded. All chemical constituents were characterized according to their mass spectra in order to ascertain their precursor ions and to select proper product ions for MRM analysis. Finally, the most sensitive transition in MRM was selected.

2.4. Method Validation {#sec2dot4-molecules-20-18597}
----------------------

### 2.4.1. Linearity and Detection Limit {#sec2dot4dot1-molecules-20-18597}

The calibration curves plotted against the standard solution were constructed from the peak area ratios of each standard *vs.* concentrations of each constituent. Therefore we can determine that this method is sensitive for the quantitative determination of the major components in STP samples. The linearity of the calibration curves were verified by correlation study, where the correlation coefficients were better than 0.9990 within the test ranges. The LODs and LOQs for the 13 compounds were less than 0.51 and 1.70 μg/L, respectively ([Table 2](#molecules-20-18597-t002){ref-type="table"}).

molecules-20-18597-t002_Table 2

###### 

Calibration curves, linear ranges, LOQ and LOD of 13 detected compounds (*n* = 3).

  Compound          Linear                  Linear Range (μg/mL)   r        LOQ (μg/mL)   LOD (μg/mL)
  ----------------- ----------------------- ---------------------- -------- ------------- -------------
  Taurine           y = 0.0707x − 0.0005    10.03--0.40            0.9999   0.1300        0.0390
  Ginsenoside Rg1   y = 0.0574x − 0.0102    7.51--0.75             0.9998   0.6000        0.1800
  Arenobufagin      y = 0.3438x − 0.0003    5.02--0.40             0.9996   0.0300        0.0090
  TDCA              y = 0.0125x − 0.0061    25.28--3.75.           0.9992   1.7000        0.5100
  TCA               y = 0.0525x − 0.0094    10.53--0.75            0.9996   0.6000        0.1800
  Bufalin           y = 1.1663x + 0.0624    4.01--0.40             0.9999   0.0032        0.0010
  CA                y = 0.0909x − 0.0211    10.07--1.01            0.9998   0.7800        0.2340
  Cinobufagin       y = 0.1767x + 0.0523    5.02--0.75             0.9998   0.0003        0.0010
  Resibufogenin     y = 0.9504x − 0.0596    4.01--0.50             0.9993   0.2100        0.0630
  Ginsenoside Rg3   y = 0.048x + 0.0256     2.01--0.01             0.9994   0.0041        0.0012
  CDCA              y = 0.2824x − 0.0241    5.01--0.75             0.9993   0.2900        0.0870
  DCA               y = 0.2049x + 0.0145    4.01--0.40             0.9990   0.0050        0.0015
  Tanshinone IIA    y = 34.5600x − 0.0030   0.05--0.01             0.9995   0.0042        0.0013

### 2.4.2. Precision, Repeatability, Stability and Recovery {#sec2dot4dot2-molecules-20-18597}

Precision, repeatability and stability of the method were also validated for each analyte. The RSDs were less than 4.88%, respectively. In conclusion, our experimental method provided high precision, repeatability, and stability. The accuracy of the method was determined by a recovery test ([Table 3](#molecules-20-18597-t003){ref-type="table"}). As shown in [Table 4](#molecules-20-18597-t004){ref-type="table"}, the recovery rate of the 13 standards varied from 98.24%--101.02% (RSD ≤ 4.48%). These results verified the high recovery and accuracy of this method.
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###### 

Precision, repeatability, stability of 13 detected components of STP.

  Analyte           Repeatability      Precision RSD%   Stability          
  ----------------- ------------------ ---------------- ----------- ------ ------
  Taurine           35.2978 ± 0.7821   2.22             2.35        2.42   2.71
  Ginsenoside RG1   8.7050 ± 0.2457    2.82             4.69        4.30   3.24
  Arenobufagin      10.9163 ± 0.2826   2.59             3.13        3.95   4.33
  TDCA              43.8546 ± 1.8145   4.14             3.96        3.08   2.47
  TCA               29.7562 ± 1.3109   4.41             4.17        3.34   3.55
  Bufalin           6.9432 ± 0.2124    3.06             3.88        4.20   3.40
  CA                33.6313 ± 0.8419   2.50             3.52        3.58   2.58
  Cinobufagin       19.1693 ± 0.4315   2.25             2.71        2.63   3.91
  Resibufogenin     8.1053 ± 0.1211    1.49             2.88        3.00   3.00
  Ginsenoside RG3   8.5907 ± 0.2642    3.08             2.63        2.60   2.25
  CDCA              14.7924 ± 0.5840   3.95             4.79        3.46   2.12
  DCA               5.7912 ± 0.1679    2.90             2.01        2.37   2.24
  Tanshinone IIA    0.0208 ± 0.0007    3.54             4.00        4.55   4.88

molecules-20-18597-t004_Table 4

###### 

Recoveries of 13 detected components of STP.

  Analyte           Original (μg)     Added (μg)   Detected (μg) (±SD *n* = 3)   Recovery (%) (±SD *n* = 9)   RSD (%)
  ----------------- ----------------- ------------ ----------------------------- ---------------------------- ---------
  Taurine           1764.89           2000.00      3734.82 ± 73.55               99.20 ± 3.00                 3.02
  1500.00           3263.21 ± 55.01                                                                           
  1000.00           2756.97 ± 27.37                                                                           
  Ginsenoside RG1   435.25            500.00       934.19 ± 22.09                98.86 ± 3.77                 3.82
  400.00            826.68 ± 12.69                                                                            
  300.00            732.04 ± 14.85                                                                            
  Arenobufagin      545.82            900.00       1422.16 ± 4.83                99.28 ± 3.49                 3.52
  600.00            1156.98 ± 26.84                                                                           
  300.00            841.64 ± 10.52                                                                            
  TDCA              2192.73           3000.00      5115.89 ± 43.01               98.64 ± 2.96                 3.00
  2000.00           4195.34 ± 57.22                                                                           
  1000.00           3176.37 ± 43.66                                                                           
  TCA               1487.81           2000.00      3435.51 ± 54.39               99.26 ± 3.31                 3.34
  1500.00           2994.86 ± 70.89                                                                           
  1000.00           2487.12 ± 24.57                                                                           
  Bufalin           347.16            500.00       843.70 ± 24.18                99.00 ± 4.18                 4.23
  400.00            744.40 ± 18.15                                                                            
  300.00            642.24 ± 15.03                                                                            
  CA                1681.57           2000.00      3682.31 ± 57.38               99.20 ± 3.09                 3.11
  1500.00           3149.48 ± 52.01                                                                           
  1000.00           2678.33 ± 37.17                                                                           
  Cinobufagin       958.47            1500.00      2428.88 ± 47.17               98.64 ± 3.38                 3.00
  1000.00           1963.89 ± 36.52                                                                           
  500.00            1434.10 ± 3.47                                                                            
  Resibufogenin     405.27            500.00       896.21 ± 13.03                98.24 ± 3.20                 3.25
  400.00            795.04 ± 12.45                                                                            
  300.00            702.54 ± 14.18                                                                            
  Ginsenoside RG3   429.54            500.00       928.54 ± 19.34                99.63 ± 3.55                 3.56
  400.00            825.86 ± 17.65                                                                            
  300.00            729.51 ± 11.68                                                                            
  CDCA              739.62            1500.00      2222.5 ± 54.47                98.67 ± 2.97                 3.01
  750.00            1475.11 ± 17.65                                                                           
  500.00            1234.91 ± 19.78                                                                           
  DCA               289.56            600.00       888.35 ± 23.94                99.38 ± 3.23                 3.25
  300.00            584.70 ± 11.05                                                                            
  150.00            439.51 ± 4.75                                                                             
  Tanshinone IIA    1.04              2.00         3.01 ± 0.09                   101.02 ± 4.53                4.48
  1.00              2.05 ± 0.05                                                                               
  0.50              1.56 ± 0.03                                                                               

2.5. Sample Analysis {#sec2dot5-molecules-20-18597}
--------------------

The established UPLC-QqQ-MS/MS analytical approach was subsequently used to determine the representative constituents in 8 batches of commercial STP products. The contents of the investigated compounds, based on their respective calibration curves are summarized in [Table 3](#molecules-20-18597-t003){ref-type="table"}. There were significant variations among the contents of constituents between different batches of STP ([Table 5](#molecules-20-18597-t005){ref-type="table"}). Among these, the main ingredients can be divided into bufadienolides, triterpene saponins, tanshinones, salvianolic acids, and bile acids. For instance, Sample 2 had the lowest contents of taurine, ginsenoside Rg1, and arenobufagin, whereas Sample 6 had the highest contents of CDCA, CA, cinobufagin, and resibufogenin. Moreover, the four bufadienolides, which includes arenobufagin, bufalin, cinobufagin, and resibufogenin, were found to be the major constituents, accounting for approximately 3.23%--14.06%, 2.75%--7.17%, 6.17%--19.17%, and 3.07%--8.11% composition of all batches, respectively. However, the contents of these four compounds varied significantly among the 13 different samples, which could result in the varying quality and efficacy of STP samples. Real sample data also demonstrated that UPLC-QqQ-MS/MS is a suitable method for the analysis of the active components in STP samples. Therefore, further studies of STP quality control should also focus on the composition of raw materials, as well as the optimization of parameters during processing and manufacturing.
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###### 

Contents of 13 analytes in different STP samples.

  Lot No. Compounds (mg/g)   Sample 1   Sample 2   Sample 3   Sample 4   Sample 5   Sample 6   Sample 7   Sample 8
  -------------------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  Taurine                    13.8735    10.0161    15.1052    14.4826    13.6382    35.2978    24.4059    17.9399
  Ginsenoside RG1            10.4003    4.7917     6.0041     5.4945     8.1709     8.7050     10.5062    9.8985
  Arenobufagin               6.5724     3.2283     3.9044     6.4789     4.8138     10.9163    7.2296     14.0551
  TDCA                       43.2012    73.8723    52.7846    76.3674    96.1933    43.8546    78.2465    32.8261
  TCA                        21.2145    21.3171    33.0645    44.2204    52.5620    29.7562    47.4044    21.5164
  Bufalin                    4.3781     5.2646     2.7532     4.9919     3.4709     6.9432     5.4234     7.1698
  CA                         13.2086    25.3780    15.5592    15.1331    16.1522    33.6313    23.6953    23.8216
  Cinobufagin                10.3166    6.1709     6.9125     11.3476    9.3716     19.1693    13.6489    15.7044
  Resibufogenin              5.0181     3.0739     3.1118     5.4689     4.1013     8.1053     6.3188     7.4538
  Ginsenoside RG3            17.1353    3.2188     8.0643     8.0672     13.4715    8.5907     13.3079    6.4563
  CDCA                       3.7939     4.6744     10.4556    6.6600     8.0945     14.7924    11.2672    5.8183
  DCA                        5.5619     3.6310     2.2421     5.1843     6.1205     5.7912     10.0939    9.4447
  Tanshinone IIA             0.0026     0.0028     0.0207     0.0031     0.0134     0.0208     0.0239     0.0154

3. Experimental Section {#sec3-molecules-20-18597}
=======================

3.1. Materials and Reagents {#sec3dot1-molecules-20-18597}
---------------------------

Reference substances of arenobufagin, bufalin, resibufogenin, cinobufagin, turo-ursodesoxycholic acid (TDCA), taurocholic acid (TCA), cholic acid (CA), chenodeoxycholic acid (CDCA), ursodesoxycholic acid (UDCA), and hyodeoxycholic acid (HDCA) were purchased from Must Bio-Technology Co., Ltd. (Chengdu, China). Tanshinone IIA, salvianolic acid B, gensenoside Rg2, and gensenoside Rh1 were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). The purity of each compound was determined to be higher than 98% by HPLC. LC-grade acetonitrile and formic acid were purchased from Merck (Darmstadt, Germany). Deionized water for HPLC analysis was purified using a Milli-Q system (Millipore, Billerica, MA, USA). Methanol for sample extraction was from Merck. STP raw materials were provided by the Inner Mongolia Conba Pharmaceutical Co., Ltd. (Inner Mongolia, China).

3.2. Preparation of Standard and Sample Solutions {#sec3dot2-molecules-20-18597}
-------------------------------------------------

Stock solutions of 13 standards (ginsenoside Rg1, ginsenoside Rk3, cinobufagin, arenobufagin, bufalin, resibufogenin, tanshinone IIA, taurine, tauroursodeoxycholic acid, taurocholic acid, cholic acid, deoxycholic acid, chenodeoxycholic acid and astragaloside as internal standard) were prepared individually by dissolving an accurately weighed amount of reference compound in methanol at concentrations of 1.397, 1.273, 0.975, 0.635, 1.272, 1.115, 0.167, 1.096, 0.885, 2.491, 1.119, 1.065, and 1.300 mg/mL, respectively. Next, aliquots of each stock solution were mixed, and diluted with methanol to achieve a series of standard working solutions for the construction of calibration curves.

In order to obtain the purest possible chemical constituents from STP extract, eight batches of STP samples were ground into fine powder without the capsule outer casing and thoroughly mixed. Next, 0.5 g powder was accurately weighed and extracted with methanol (50 mL) in an ultrasonic water bath (40 kHz, 500 W) for 30 min at room temperature. The samples were then centrifuged at 16,000× *g* for 10 min after replenishing methanol. The solution was incubated for 24 h at 4 °C and the resulting supernatant was used as the sample solution for LC/MS analysis. The resulting solution was filtered through a membrane with 0.22 µm pores prior to use. Sample injected volume was 6 µL.

3.3. Qualitative and Quantitative Analysis Conditions {#sec3dot3-molecules-20-18597}
-----------------------------------------------------

### 3.3.1. HPLC Method for Qualitative Analysis {#sec3dot3dot1-molecules-20-18597}

HPLC-Q-TOF-MS/MS method for qualitative analysis was performed using a LC20AT HPLC instrument (Shimadzu, Kyoto, Japan) coupled with a micro-TOF-QII mass spectrometer (Bruker, Karlsruhe, Germany) equipped. The HPLC instrument includes a binary pump, an online degasser, and a thermostatically controlled column compartment. Chromatographic separation was carried out at 25 °C on an Inertsil ODS-SP C18 column (4.6 mm × 250 mm, 5 µm, GL Sciences Inc., Kyoto, Japan). The chromatographic conditions were as follows: flow rate of 0.8 mL/min, sample injection volume of 6 µL, mobile phase A (0.1% formic acid-water) and mobile phase B (100% acetonitrile) with a gradient elution program as follows: 0--5 min, 5%--5% B; 5--10 min, 5%--25% B; 10--60 min, 25%--48% B; 60--80 min, 48%--57% B; 80--100 min, 57%--90% B. Re-equilibration duration was 10 min between individual runs.

### 3.3.2. Q-TOF Method for Qualitative Analysis {#sec3dot3dot2-molecules-20-18597}

The micrOTOF-Q II mass spectrometer was equipped with electrospray ionization (ESI) source and operated in positive and negative mode. For the negative ion mode MS detection, the optimized operating parameters were as follows: capillary, +3500 V; end plate offset, +500 V; transfer time of 80 µs. For the positive ion mode, the optimized operating parameters were as follows: capillary, −4500 V; end plate offset, −500 V; transfer time of 120 μs. For both negative and positive ion mode, the same operation parameters were as follows: drying gas (N2) flow rate, 4.0 L/min; drying gas temperature, 180 °C; nebulizer, 2.0 Bar; hexapole Rf, 100.0 Vpp; quadrupole ion energy, 3.0 eV; collision Rf, 150.0 Vpp; prepulse storage time, 5μs. Argon was applied as the collision gas, The sample collision energy was set at 25--55 eV to obtain the fragment ions data. Acquisition and analysis of data was performed with Data Analysis Version 4.0 SP1 (Bruker Technologies). Each sample was analyzed in both positive and negative modes to provide abundant information for structural identification. Mass spectra were recorded across the range 50--1500 *m*/*z* with accurate mass measurement of all mass peaks. Accurate mass measurements of each peak from the total ion chromatogram (TIC) were obtained by means of an automated calibration delivery system using a dual-nebulizer ESI source that introduces a low flow (100 μL/min) of a calibrating solution (sodium formate solution, Bruker Technologies), which was performed daily before sample injection, and contains the internal reference masses at *m*/*z* 90.9766 and 1518.7125 in positive ion mode and *m*/*z* 112.9856 and 1472.7341 in negative ion mode.

### 3.3.3. UPLC-MS Method for Quantitative Analysis {#sec3dot3dot3-molecules-20-18597}

UPLC-QqQ-MS/MS method was used for qualitative analysis, and a Waters (Milford, MA, USA) Acquity UPLC H-Class system coupled with Xevo TQD QqQ-MS with ESI was employed. Separations were accomplished on Waters CORTECS C18 (2.1 mm × 100 mm, 1.6 μm) at a flow rate of 0.25 mL/min. The column temperature was maintained at 45 °C. The mobile phase was acetonitrile (phase A) and water (containing 0.1% formic acid, phase B) with a gradient elution program as follows: 0--3 min, 30%--30% A; 3--5 min, 30%--70% A; 5--6 min, 70%--85% A; 6--7 min, 85%--85% A; 7--8 min, 85%--100% A, 8.01--10 min, 30%--30% A. The MS spectra were acquired in multiple reaction monitoring (MRM) mode. The collision gas was argon. The nebulizer gas and the heater gas both were nitrogen. The MS conditions were optimized as follows: capillary voltage 2500 V in positive ion mode; source temperature, 150 °C; dwell time, 20 ms, dry gas flow, 800 L/h, the temperature of dry gas, 200 °C. The most appropriate setting such as precursor ion, daughter ion, cone voltage, collision energy (CE) was adjusted according to each analyte ([Table 6](#molecules-20-18597-t006){ref-type="table"}).

molecules-20-18597-t006_Table 6

###### 

The transitions and optimized MS parameters of 13 target markers and internal standard in the UPLC-QqQ-MS/MS analysis.

  Compounds         Rt (min)   Precursor Ion (*m*/*z*)   Daughter Ion (*m*/*z*)   Con Voltage (V)   Collision Energy (eV)
  ----------------- ---------- ------------------------- ------------------------ ----------------- -----------------------
  Taurine           0.82       126.00                    108.20                   22                14
  Ginsenoside Rg1   1.25       823.30                    643.50                   80                40
  Arenobufagin      2.23       417.20                    399.10                   45                30
  TDCA              3.39       522.28                    486.61                   50                25
  TCA               3.41       538.00                    538.00                   60                2
  Astragaloside     4.91       807.00                    807.00                   80                30
  Bufalin           5.22       387.30                    351.20                   35                22
  CA                5.41       391.30                    355.30                   0                 20
  Cinobufagin       5.56       443.50                    365.20                   60                20
  Resibufogenin     5.59       385.30                    367.20                   35                18
  Ginsenoside Rg3   5.75       807.00                    365.00                   90                5
  CDCA              6.13       357.60                    161.20                   40                20
  DCA               6.23       357.60                    161.20                   40                20
  Tanshinone IIA    7.28       295.10                    277.00                   40                20

3.4. Validation of Quantitative Method {#sec3dot4-molecules-20-18597}
--------------------------------------

### 3.4.1. Calibration Curve, LOD, and LOQ {#sec3dot4dot1-molecules-20-18597}

For the calibration curves, at least six concentrations of calibration standard solution were made and analyzed in triplicate. Next, the calibration curve of each analyte was constructed by plotting the peak area *vs.* the corresponding concentration.

The mixed standard solution with the lowest concentration was further diluted to a certain concentration to evaluate the LODs and LOQs. The LODs and LOQs were determined at an S/N ratio of 3 and 10, respectively.

### 3.4.2. Precision, Stability, Repeatability, and Recovery {#sec3dot4dot2-molecules-20-18597}

The analysis of intra- and inter-day precisions was carried out by six repetitive injection of a mixed standard solution, in the same day and once a day for three consecutive days, respectively. Both assays were determined by performing three different concentration levels of the standards. Six samples were prepared independently to verify the repeatability of the experiment. To investigate the stability of the samples, each sample solution was analyzed every 4 h within 24 h, and stored at room temperature. The recovery was used to evaluate the accuracy of the method, and was determined by adding the mixed standard solutions at three different concentration levels (low, medium, and high) to 0.10 g of the known amounts of STP sample (Sample 6). The mixture was then extracted and analyzed. Three replicates were performed at each level. The percentages of recovery were calculated according to the following equation: (found amount − original amount) × 100%/spiked amount. The RSD was used to evaluate the results.

4. Conclusions {#sec4-molecules-20-18597}
==============

Our study demonstrates for the first time, the chemical profile of STP through a thorough and systematic investigation using HPLC-Q-TOF-MS/MS. In this study, a rapid and sensitive method based on HPLC-Q-TOF-MS/MS and UPLC-QqQ-MS/MS was established for the separation, identification and determination of the chemical constituents of STP. We identified a total of 41 components, including triterpene saponins, bufadienolides, bile acids, phenylally compounds and other compounds, which were successfully separated and identified by HPLC-Q-TOF-MS/MS. We also established the optimized UPLC-QqQ-MS/MS method for simultaneous determination of 13 compounds in STP under optimized UPLC conditions. The MRM mode of QqQ-MS/MS using our method enabled identification of target compounds with high sensitivity even at low concentrations, through comparison with standards. Rapid analysis performed within 10 min also facilitated the efficient quantitation of the target compounds in STP. This analytical method also verified its efficiency through method validation (linearity, precision and recovery test). Consequently, our method provided an accurate and efficient tool for the quality control of STP. The results of this study will aid in the discovery and analysis of biologically active compounds in STP, as well as facilitating improvements in the quality control standard of this commonly used multi-component TCM formula.
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